Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Hydrochlorothiazide + reserpine** is an oral combination drug used primarily to treat **hypertension (high blood pressure)**. Hydrochlorothiazide is a thiazide diuretic ("water pill") that works by increasing urine production, reducing fluid volume, and thus lowering blood pressure. Reserpine, a rauwolfia alkaloid, acts centrally by irreversibly blocking VMAT2 (vesicular monoamine transporter 2), depleting monoamine neurotransmitters such as norepinephrine, dopamine, and serotonin from nerve endings, resulting in reduced sympathetic nervous system activity and lower blood pressure. This combination is effective at reducing both systolic and diastolic blood pressure, and has shown comparable efficacy to other antihypertensive regimens in clinical studies[3][6]. It is no longer marketed in the United States but is still in use in some countries[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrochlorothiazide + reserpine.